ivonescimab

From Aaushi
Jump to navigation Jump to search
[1]

Indications

  • intestigational treatment of advanced PD-L1-positive advanced NSCLC

* improvement in progression-free survival vs pembrolizumab (median of 11.1 vs 5.8 months) in phase-3 trial[1]

Dosage

  • 20 mg/kg every 3 weeks

Adverse effects

Mechanism of action

More general terms

References

  1. ↑ 1.0 1.1 Brooks M Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC. Medscape. Sept 12, 2024 https://www.medscape.com/viewarticle/ivonescimab-possible-new-first-line-standard-pd-l1-positive-2024a1000g7m
Retrieved from "https://aaushi.info/w/index.php?title=A58912&oldid=1222415"